4.7 Article

Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study

Journal

JOURNAL OF AFFECTIVE DISORDERS
Volume 138, Issue 1-2, Pages 86-95

Publisher

ELSEVIER
DOI: 10.1016/j.jad.2011.12.021

Keywords

TORDIA; Trajectories; Latent class analysis; Depression; Adolescent

Funding

  1. Phillip Morris
  2. Pfizer
  3. National Institute of Mental Health: is a consultant for Schering Plough
  4. Random House, Inc. (New Hope for Children and Teens with Bipolar Disorder)
  5. Lippincott Williams & Wilkins (Treating Child and Adolescent Depression)
  6. Guilford Press
  7. UpToDate Psychiatry
  8. NIMH [MH61835, MH6185E, MH61864, MH61869, MH61958, MH62014]
  9. Advanced Center for Early-Onset Mood and Anxiety Disorders [MH66371]
  10. Hikma pharmaceuticals
  11. Biobehavioral Diagnostics
  12. Eli Lilly
  13. Forest Laboratories
  14. GlaxoSmithKline
  15. Somerset

Ask authors/readers for more resources

Background: To identify distinct depressive symptom trajectories in the TORDIA study and determine their correlates. Methods: Latent Class Growth Analysis (LCGA) using the Children's Depression Rating Scale Revised (CDRS-R) through 72 weeks from intake. Results: 3 classes were identified: (1) little change in symptomatic status (NO), comprising 24.9% of participants, with a 72-week remission rate of 25.3%; (2) slow, steady improvement (SLOW), comprising 47.9% of participants, with a remission rate of 60.0%, and (3) rapid symptom response (GO), comprising 27.2% of participants, with a remission rate of 85.7%. Higher baseline CDRS-R (p<0.001) and poorer functioning (p = 0.03) were the strongest discriminators between NO and GO. Higher baseline CDRS (p<0.001) and scores on the Mania Rating Scale (MRS) (p = 0.01) were the strongest discriminators between SLOW and GO. Other variables differentiating GO from both NO and from SLOW, were better baseline functioning, lower hopelessness, and lower family conflict. Both NO and SLOW showed increases on the MRS over time compared to GO (ps <= 0.04), and increasing MRS was strongly associated with lack of remission by 72 weeks (p = 0.02). Limitations: High rate of open treatment by the end of the follow-up period creates difficulty in drawing clear inferences about the long-term impact of initial randomization. Conclusion: Along with depressive severity, sub-syndromal manic symptoms, at baseline, and over time emerged as important predictors and correlates of poor outcome in this sample. Further research is needed on the treatment of severe depression, and on the assessment and management of sub-syndromal manic symptoms in treatment resistant depression. (C) 2011 Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available